摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(1-哌啶甲基)苯硼酸频哪醇酯 | 859833-22-0

中文名称
4-(1-哌啶甲基)苯硼酸频哪醇酯
中文别名
4-(哌啶甲基)苯硼酸频那醇酯
英文名称
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidine
英文别名
1-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]piperidine
4-(1-哌啶甲基)苯硼酸频哪醇酯化学式
CAS
859833-22-0
化学式
C18H28BNO2
mdl
MFCD08271932
分子量
301.237
InChiKey
HJKVRMHVLINDRH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    63 °C
  • 沸点:
    394.1±25.0 °C(Predicted)
  • 密度:
    1.03±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.51
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.666
  • 拓扑面积:
    21.7
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    C
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:f4c152c601e28c21d22673357f25ae72
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(Piperidinomethyl)phenylboronic acid, pinacol ester
Synonyms: 1-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]piperidine

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-(Piperidinomethyl)phenylboronic acid, pinacol ester
CAS number: 859833-22-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C18H28BNO2
Molecular weight: 301.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(1-哌啶甲基)苯硼酸频哪醇酯N,N-二甲基乙酰胺 、 Cu(OTf)2(py)4 作用下, 以 乙腈 为溶剂, 反应 0.33h, 生成 1-(4-[18F]fluorobenzyl)piperidine
    参考文献:
    名称:
    消除杂环正电子发射断层扫描放射性配体的铜介导的 18F-氟化
    摘要:
    用氟 18 (18F) 标记的分子用于正电子发射断层扫描,以可视化、表征和测量体内的生物过程。尽管最近在将 18F 掺入芳烃方面取得了进展,但开发通用且有效的方法来标记药物发现计划所需的放射性配体仍然是一项重大任务。这个完整的描述描述了杂环正电子发射断层扫描 (PET) 放射性配体的放射合成方法,使用铜介导的 18F 氟化芳基硼试剂与 18F 氟化物作为模型反应。该方法基于一项研究,该研究检查了药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 18F-氟化效率,以及超过 50 种(杂)芳基硼酸酯的标记。这组数据允许将这种去风险策略应用于七种结构复杂的药物相关含杂环分子的成功放射合成。
    DOI:
    10.1021/jacs.7b03131
  • 作为产物:
    描述:
    4-羟甲基苯硼酸 在 [ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2 、 sodium carbonate 、 双(2-二苯基磷苯基)醚 作用下, 以 5,5-dimethyl-1,3-cyclohexadiene甲苯 为溶剂, 反应 26.0h, 生成 4-(1-哌啶甲基)苯硼酸频哪醇酯
    参考文献:
    名称:
    Synthesis of Amines with Pendant Boronic Esters by Borrowing Hydrogen Catalysis
    摘要:
    Amine alkylation reactions of alcohols have been performed in the presence of boronic ester groups to provide products which are known to have use as molecular sensors. The boronic ester moiety could be present in either the alcohol or amine starting material and was not compromised in the presence of a ruthenium catalyst.
    DOI:
    10.1021/ol402271a
点击查看最新优质反应信息

文献信息

  • Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats
    作者:Aziz Ouach、Johnny Vercouillie、Emilie Bertrand、Nuno Rodrigues、Frederic Pin、Sophie Serriere、Liliana Boiaryna、Agnes Chartier、Nathalie Percina、Pakorn Tangpong、Zuhal Gulhan、Celine Mothes、Jean-Bernard Deloye、Denis Guilloteau、Guylene Page、Franck Suzenet、Frederic Buron、Sylvie Chalon、Sylvain Routier
    DOI:10.1016/j.ejmech.2019.06.049
    日期:2019.10
    and nine of them exhibited Ki values below nanomolar concentrations. The best scores were always obtained when the 5-phenyl-2-thiophenyl core was attached to the triazole. The selectivity of these compounds towards the nicotinic α4β2 and serotoninergic 5HT3 receptors was assessed and their brain penetration was quantified by the preparation and in vivo evaluation of two [18F] radiolabelled derivatives
    在本文中,我们描述了使用有效的三步序列(包括与市售的硼衍生物和自制的硼衍生物的Suzuki-Miyaura交叉偶联反应)设计和合成双(Het)芳基-1,2,3-三唑喹核苷α7R配体的方法。 。SAR的勘探需要制备罕见的硼衍生物。测试了40种最终药物结合靶标的能力,其中9种药物的Ki值低于纳摩尔浓度。当将5-苯基-2-硫代苯基核心连接到三唑上时,总会获得最高分。通过制备和体内评估两种化合物,评估了这些化合物对烟碱型α4β2和5羟色胺能5HT3受体的选择性,并定量了它们的脑渗透率[ 18F]放射性标记的衍生物。从我们的结果可以预期,这些化合物中的一些将适合进一步发展,并将对认知障碍产生影响。
  • [EN] HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES COMME INHIBITEURS DE MK2
    申请人:NOVARTIS AG
    公开号:WO2009010488A1
    公开(公告)日:2009-01-22
    The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.
    本发明描述了式(IA)或(IB)的四环化合物,其中符号R、X、A、Y、R2、R3和D如规范中所定义,它们在治疗某些疾病中的用途,例如取决于MK-2或TNF活性,并制造它们的方法。
  • Photoredox-catalyzed Direct Reductive Amination of Aldehydes without an External Hydrogen/Hydride Source
    作者:Rauful Alam、Gary A. Molander
    DOI:10.1021/acs.orglett.8b00895
    日期:2018.5.4
    The direct reductive amination of aromatic aldehydes has been realized using a photocatalyst under visible light irradiation. The single electron oxidation of an in situ formed aminal species generates the putative α-amino radical that eventually delivers the reductive amination product. This method is operationally simple, highly selective, and functional group tolerant, which allows the direct synthesis
    使用光催化剂在可见光照射下已经实现了芳族醛的直接还原胺化。原位形成的缩醛胺物种的单电子氧化产生推定的α-氨基自由基,最终传递还原性胺化产物。该方法操作简单,高度选择性且具有官能团耐受性,可通过独特的机理途径直接合成苄基胺。
  • [EN] PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] DÉRIVÉS PYRAZOLOPYRIMIDINE UTILES COMME INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
    申请人:REDX PHARMA LTD
    公开号:WO2014188173A1
    公开(公告)日:2014-11-27
    This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    这项发明涉及新型化合物。该发明的化合物是酪氨酸激酶抑制剂。具体来说,该发明的化合物可用作布鲁顿酪氨酸激酶(BTK)的抑制剂。该发明还考虑了利用这些化合物治疗通过抑制布鲁顿酪氨酸激酶可治疗的疾病,例如癌症、淋巴瘤、白血病和免疫性疾病。
  • Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor
    作者:Jinsong Han、Ying Chen、Chao Yang、Ting Liu、Mingping Wang、Haojie Xu、Ling Zhang、Canhui Zheng、Yunlong Song、Ju Zhu
    DOI:10.1016/j.ejmech.2016.06.030
    日期:2016.10
    superior pharmacokinetic profiles for animal studies. It significantly inhibited tumor growth when administered orally in an A549 non-small-cell lung carcinoma xenograft and BEL7404 human hepatocellular carcinoma xenograft models. On the basis of its excellent in vivo efficacy and superior pharmacokinetic profiles, 13b has been selected for further preclinical investigation as a promising anticancer drug
    磷酸肌醇3-激酶(PI3K)家族是广泛的人类癌症中最常被激活的酶之一。因此,抑制PI3K代表了一种有前途的癌症治疗策略。在本文中,设计了一系列苄胺取代的芳基磺酰胺类化合物,并使用整合了重点文库设计和虚拟筛选的策略合成了PI3K / mTOR双重抑制剂,从而发现了13b(NSC765844)。化合物13b对PI3Kα,β,γ,δ和mTOR的IC 50分别具有1.3、1.8、1.5、3.8和3.8 nM的强酶抑制作用。通过体外细胞毒性筛选程序在NCI中进一步评估了13b。GI平均的广谱抗肿瘤活性发现针对大约60个人类肿瘤细胞系的50值为18.6nM。图13b显示了用于动物研究的有利的理化性质和优异的药代动力学特征。当在A549非小细胞肺癌异种移植和BEL7404人肝细胞癌异种移植模型中口服给药时,它可以显着抑制肿瘤的生长。基于其出色的体内功效和出色的药代动力学特征,13b已被选作有希望的抗癌药物候选物,用于进一步的临床前研究。
查看更多